Seeking Alpha

Bryce_in_TX

Bryce_in_TX
Send Message
View as an RSS Feed
View Bryce_in_TX's Comments BY TICKER:
Latest  |  Highest rated
  • Galena: Setting The Record Straight [View article]
    jackryanjr,

    I think you are distorting things. The fact that the Doctor works in the Financial Industry for the same company that underwrites Galena, (is that true, can you provide some support to substantiate that claim? how about a link or links to support it instead of just making a statement, some of which I have already shown to be false), and then assuming she is corrupt is guilt by association. I don't consider such reasoning valid, generally.

    The 2013 10-K states the Neuvax Phase III Present Trial is "Ongoing" and still enrolling. It's not a goal, it is in the enrollment process now and has been since 2011. This is backed up by clinicaltrials.gov.

    ""Phase 3 Ongoing: Based on our Phase 2 trial, which achieved its primary endpoint of DFS, the U.S. Food and Drug Administration (FDA) granted NeuVax a Special Protocol Assessment (SPA) for its Phase 3 PRESENT (Prevention of Recurrence in Early- Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study. The multinational, multicenter PRESENT trial is ongoing in North America, Western and Eastern Europe, and Israel. Additional information on the study can be found at http://www.neuvax.com." (See page 5)

    http://1.usa.gov/1dehUsU

    http://1.usa.gov/1bfG30X

    Please do a better interpretation of the facts, or I'll have to assume you are trying to discredit individuals associated with GALE through illegitimate means.
    Mar 19 09:01 PM | 1 Like Like |Link to Comment
  • Galena: Setting The Record Straight [View article]
    "If it does, the market cap of GALE today exceeds the revenue potential thereof."

    You keep making statements with no support to back them up.

    I sold my GALE stock because I lost confidence in Ahn and company. However, i think your view of the company is a bit too dark, probably clouded by your assessment of Ahn and company.

    "If their primary target was that micro-population, they would already be moving forward with a Ph3 under a SPA,"

    You are saying that the doctors should have understood what populations would most benefit from the vaccine before any study was performed. It works just the opposite.
    Mar 19 08:29 PM | Likes Like |Link to Comment
  • Cramer Dumps Linn, Should You? [View article]
    LINE is borrowing to pay for the puts. But that borrowed money is never included in calculating DCF. LINE argues the puts are PP&E and that the puts amortization are just like DD&A for PP&E and should not be included in the calculation of DCF.

    So, they count the revenue from the borrowed money but not the cost of the borrowed money ($583 million of puts) in their DCF calculation. They want the benefit from the borrowed money without including its cost. As I said, I know of no accounting principle or theory that would permit recording only the proceeds from the derivative while ignoring the cost.
    Mar 19 08:21 PM | Likes Like |Link to Comment
  • Galena: Setting The Record Straight [View article]
    jackryanjr,

    "Sadly, their is no SPA in place for any Galena trial. It is stated as a 2014 GOAL in their Q10."

    I think you are wrong. Here is what the 2013 10-K states on page 5:

    "Phase 3 Ongoing: Based on our Phase 2 trial, which achieved its primary endpoint of DFS, the U.S. Food and Drug Administration (FDA) granted NeuVax a Special Protocol Assessment (SPA) for its Phase 3 PRESENT
    (Prevention of Recurrence in Early- Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study. The multinational, multicenter PRESENT trial is ongoing in North America, Western and Eastern Europe, and Israel. Additional information on the study can be found at http://www.neuvax.com."

    Note it says an SPA was "granted", past tense, for the Trial. Also, note it says the Phase III Trial is "Ongoing". They are still enrolling patients.

    http://1.usa.gov/1dehUsU

    If you are going to make statements about what a reference, such as the 10-K, states I would suggest quoting the reference, including a link to it, so that everyone can evaluate the credibility of your statement.
    Mar 19 07:51 PM | 2 Likes Like |Link to Comment
  • Galena: Setting The Record Straight [View article]
    serpinator,

    Neuvax being a long shot is your opinion, but I don't see it in the data. As the study link states, 65% of patients did not receive the optimal dose in the phase II study, yet at the 18 month mark it was shown to have clinical efficacy with a p value of .04. Most vaccines require boosters, as did the small pox vaccine I received at age 20. As stated from page 2595 of the study:

    "Later, it was observed that late recurrences in the vaccinated group corresponded to waning immunity, as demonstrated by decreased levels of E75-specific cytotoxic T lymphocytes (CTLs). This finding suggested that a booster inoculation may be necessary to maintain significant immunity. Toward that end, we instituted a booster program and recently reported the booster to be safe and effective in restimulating E75-specific immunity in patients who had failed to maintain significant residual immunity after initial vaccination."

    http://bit.ly/1gry7fp

    This states the booster was successful in restimulating immunity in those who had failed to maintain immunity after the initial vaccination. So, I have no clue what you mean by Neuvax being a long shot. And the doctors' conclusion at study end was:

    "CONCLUSIONS:
    The E75 vaccine has clinical efficacy that is more prominent in certain patients."

    As far as a pump and dump, that is an "assumption" which appears to me to have little validity, if any. I will challenge you to show me how the DTG materially impacted GALE's stock price. Show me. Correlate the DTG efforts to GALE's stock price. Show me where the marketing impacted the stock price materially. You might want to visit my blog to see what I discovered in researching GALE's stock price and trying to correlate it to the DTG marketing campaign.

    http://bit.ly/1qmuWaQ
    Mar 19 07:13 PM | 1 Like Like |Link to Comment
  • Behind The Scenes With Dream Team, CytRx And Galena [View article]
    scott

    "Bryce, you panic sold....in a few months you will wish you would have waited to sell when it is 5 bucks "

    You also told me that I would be regretting my sell yesterday. I was very clear why I sold, due to my loss of confidence in the management. If heads roll, I will rethink GALE, but not until then. I am glad to be out with all the volatility, because of current management. I can debate the virtues of Neuvax or Abstral, but I can't debate DTG or the stock sales.
    Mar 19 06:51 PM | 3 Likes Like |Link to Comment
  • Galena: Setting The Record Straight [View article]
    "E75 is just a peptide derivative of the HER-2 antigen, and yet for their NeuVax breast cancer recurrence prevention trial, they are looking only at HER-2-negative tumors. This does not make any sense at all."

    See the 12:55 mark and after for an answer to your question on Her-2 overexpression:

    http://bit.ly/1ms0612

    It's also in the study results on page 2600:

    "Interestingly, despite the finding that this vaccine targets HER2, our
    previously reported data suggest that patients whose tumors have low HER2 expression mount a more robust immunologic response after vaccination than do patients whose tumors overexpress HER2. Patients with HER2 low-expressing tumors demonstrated significantly larger
    delayed-type hypersensitivity responses after completion of the vaccination series as well as more sustained long-term E75-specific CTL responses."

    "We have previously hypothesized that patients with ER2-overexpressing tumors have some element of immunologic tolerance."

    http://bit.ly/1gry7fp

    It's believed that the HER-2 overexpressing patients have a higher immunological tolerance than those they are targeting, meaning, as best I can understand, that the vaccine is not as effective in such patients in developing the immune response.

    "They have only one profitable approved product: sublingual fentanyl. Doesn’t appeal to me in the least."

    I know of a cancer patient on this forum who thinks it is the best thing for the breakthrough pain, very quick, within minutes, doesn't make him or her (want to keep the patient's anonymity) zone out the entire day, only 20 minutes or so, and then he or she can go about their day. He or she thinks it is the best medication he or she has used for the breakthrough pain. Much easier to use than Subsys and disposal is much easier since the pill dissolves under the tongue.
    Mar 19 05:22 AM | 5 Likes Like |Link to Comment
  • Cramer Dumps Linn, Should You? [View article]
    "It is not added back in to cash, it offsets values in the "Discretionary adjustments" because the number you are looking at is not a cost, it is the value of an investment."

    Yes, it is added back to figure if they have sufficient DCF. Note on page 64 of the 10K, at the bottom of 2012, the $82,340 of "Excess (shortfall) of net cash provided by operating activities after distributions to unitholders and discretionary adjustments considered by the Board of Directors." All you need are the first 9 words, "Excess (shortfall) of net cash provided by operating activities". They count the cash paid for put options in the DCF formula. I don't know why you are trying to twist things, but to me you are. It's obvious this is part of the DCF calculation. You can't see it. Fine. I can't try and reason with someone who makes no sense to me.

    "They do not consider it part of DCF or they would have distributed $500m+"

    They distributed $596,935,000 in 2012. They did distribute $500m +. Again, i can't try and reason with someone who makes no sense. I'm out.
    Mar 19 12:02 AM | Likes Like |Link to Comment
  • Galena: Setting The Record Straight [View article]
    "It's a hellish time for those folks who were conned by positive spin articles to buy in at $4, $5, and above $6."

    If you are referring to GALE, I don't find that much influence that the DTG articles had on GALE's price. The assumption that the DTG work significantly influenced the stock price was my assumption as well before doing this research. You will have to show me where and how the DTG articles influenced the stock price to believe that a lot of people were conned by the spin articles. And the articles themselves I don't believe were "spin", but factual.

    There was a lot of institutional buying in GALE in the 4th quarter.

    I still have this blog even though I've sold out of the stock now. Take a look at how GALE's pipeline of products appears to have propelled the price higher, not so much the DTG articles. There are a few links which no longer work because they were DTG articles (I wasn't aware at the time that they were created by DTG)

    http://bit.ly/1qmuWaQ

    Institutional ownership seems to have disappeared in the link except for mutual funds. Here's a link to institutional ownership:

    http://bit.ly/1qSqzof
    Mar 18 11:07 PM | 3 Likes Like |Link to Comment
  • Cramer Dumps Linn, Should You? [View article]
    Dsandman999,

    "It is not added back in to cash, it offsets values in the "Discretionary adjustments" because the number you are looking at is not a cost, it is the value of an investment."

    I am weary with arguing. Yes, it is a cost. It is an asset under GAAP and tax regs, but all assets cost money. On a cash basis, there are no assets. What is paid out in cash becomes an expense immediately.

    Sorry, but I see it differently than you and all the ramblings wear me out. I'm out.
    Mar 18 10:55 PM | Likes Like |Link to Comment
  • Galena: Setting The Record Straight [View article]
    Dude,

    I respect the author of this article, highly. If you can't, I'd suggest keeping your comments to yourself.

    In the first 18 months of the Phase II Neuvax trial, Neuvax was found to be clinically effective with a p value of .04. They followed the protocols. Then later:

    "Later, it was observed that late recurrences in the vaccinated group corresponded to waning immunity, as demonstrated by decreased levels of E75-specific cytotoxic T lymphocytes (CTLs). This finding suggested that a booster inoculation may be necessary to maintain significant immunity. Toward that end, we instituted a booster program and recently reported the booster to be safe and effective in restimulating E75-specific immunity in patients who had failed to maintain significant residual immunity after initial vaccination."

    So, it appears that the vaccines strength was decreasing over time. With boosters instituted they were found to be effective in restimulating immunity. That explains the reason for the p value rising over .05 at the 24, 36 and 60 month marks.

    The doctors' conclusion (see the list of doctors on the study) was:

    "CONCLUSIONS:
    The E75 vaccine has clinical efficacy that is more prominent in certain patients."

    http://bit.ly/1gry7fp

    You know more than the docs do you? You certainly have all the attributes of a GALE basher to me.
    Mar 18 10:00 PM | 5 Likes Like |Link to Comment
  • Galena: Setting The Record Straight [View article]
    I am always suspect of first time posters on a controversial thread be they pro or con on the subject. Hang around here long enough and you will be too. I have no position in GALE. I do believe in its pipeline of products, but not its management.
    Mar 18 09:45 PM | 3 Likes Like |Link to Comment
  • Behind The Scenes With Dream Team, CytRx And Galena [View article]
    P Man,

    I have never been negative on GALE's pipeline. I consider myself to have been duped by the management in regards to DTG. If calling a spade a spade is bashing then there's nothing I can do about that. I'd like to see all GALE top management leave the company, for the good and the sake of the patients and doctors involved with the on going trials.

    I don't care what you think about my credibility. I just thought the statements by Abraxix were a bit "out there".

    Keep drinking the GALE management kool-aid. These are some of the dumbest decisions I have seen a company management make in a while.
    Mar 18 05:13 PM | 3 Likes Like |Link to Comment
  • Behind The Scenes With Dream Team, CytRx And Galena [View article]
    Abraxix,

    Try and stay within the boundaries of reality, rather than fantasy. If you want to be taken seriously, what you say needs to have some credibility. A short group corrupting DTG is simply not credible or believable, not even to the GALE bulls, I don't think.

    If Ahn and company didn't know, after reading published DTG articles, that a disclaimer was necessary, then they are some of the most incompetent management I have seen in a while. Stock sales the same. What the heck were they thinking that 6 insiders could sell at the same time? Just dumb. At best these guys are clueless, a few bricks short of a full load. And that scenario just doesn't fly with me, that they were so clueless. They need to go, IMO.
    Mar 18 04:24 PM | 1 Like Like |Link to Comment
  • Cramer Dumps Linn, Should You? [View article]
    "No, they subtracted Distributions from the CFO, then a set of discretionary adjustments which included the premiums. Your example varies, they have chosen to keep the Distribution the same and they "adjust" the expenses, even borrowing to keep the amount working without change. The premiums are in that set of expenses."

    Look at page 64 of LINE's 2013 10-K. See the columns 2013, 2012, 2011 under "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued"? Look at 2012. See "Premiums Paid for Derivatives" of $583,434? That is ADDED to "Excess (shortfall) of net cash provided by operating activities after distributions to unitholders, NOT SUBTRACTED. It IS NOT an expense here but considered as available cash for distribution. Note that Discretionary reductions for a portion of oil and natural gas development costs is in parenthesis and is deducted from cash available for distribution. But the put premiums are not in parenthesis, they are ADDED.

    http://1.usa.gov/1d98Xks

    It is as I stated:
    "In 2012, LINE spent $583 million on puts. That was deducted from Cash Flow from Ops (CFO), but LINE added it back for DCF."

    My words:"Accrual, Tax, or cash basis accounting, there is no accounting principle that would allow only recognizing the proceeds from the derivative while ignoring the cost."

    Your Response: "Obviously there is because they have the year end statements where they both don't and do in their SEC filings."

    No, there is no principle or theory that recognizes the proceeds while ignoring the costs. It is LINE ONLY who thinks they can get away with it through non-GAAP shenanigans. They never account for the cost of the put options in their calculation of DCF. LINE says they are FREE and don't matter. Baloney.

    As long as they can keep borrowing, issuing equity, and or sell assets, they may be able to keep the cash shell shuffling game going, maybe.

    However, to state that profit doesn't matter to an MLP? Totally not credible. You have to break even at the least to keep the entity solvent. You have to.
    Mar 18 02:46 AM | Likes Like |Link to Comment
COMMENTS STATS
2,374 Comments
3,003 Likes